Literature DB >> 3412413

Prevalence, morphologic types, and evolution of cardiac valvular disease in systemic lupus erythematosus.

E Galve1, J Candell-Riera, C Pigrau, G Permanyer-Miralda, H Garcia-Del-Castillo, J Soler-Soler.   

Abstract

We performed echocardiography prospectively 4.9 +/- 0.7 years apart (mean +/- SD), in 74 patients with systemic lupus erythematosus. On the basis of the first study, the patients were distributed in four groups according to the type of valvular involvement: 7 patients had vegetations (Libman-Sacks endocarditis; group 1); 6 patients had rigid and thickened valves with stenosis, regurgitation, or both (group 2); 5 patients had miscellaneous forms of valvular involvement without valvular dysfunction (group 3), as did the 60 controls; and 56 patients had no valvular disease (group 4). The overall prevalence of clinically important valvular disease (groups 1 and 2) was 18 percent. Patients in group 1 were younger than those in group 2 (33.5 +/- 16.7 vs. 47.8 +/- 17.6 years; P less than 0.05), had a shorter mean duration of lupus (4.8 +/- 2.2 vs. 10.7 +/- 6.4 years; P less than 0.001), and had received a smaller cumulative dose of steroids (21.5 +/- 13.1 vs. 79.5 +/- 63.4 g of methylprednisolone or its equivalent; P less than 0.05). During the five-year follow-up, one patient in group 1 and five in group 2 required valve surgery, no patient in group 3 had valvular dysfunction, and five patients in group 4 had mild valvular lesions. We conclude that clinically important valvular involvement in systemic lupus is relatively frequent and sometimes requires surgery. Echocardiography can identify a subset of lesions (valvular thickening and dysfunction), other than verrucous (Libman-Sacks) endocarditis, that are prone to hemodynamic deterioration.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3412413     DOI: 10.1056/NEJM198809293191302

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  32 in total

Review 1.  Cardiac valvulopathy in the antiphospholipid syndrome.

Authors:  Shaul Lev; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

2.  [Cardiovascular monitoring of patients with systemic lupus erythematosus].

Authors:  H Schotte; H Becker; W Domschke; M Gaubitz
Journal:  Z Rheumatol       Date:  2005-11       Impact factor: 1.372

3.  Heart valve disease in systemic lupus erythematosus. Role of antiphospholipid antibodies.

Authors:  O Meyer; M Golstein; P Nicaise; C Labarre; M F Kahn
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

4.  Infective endocarditis, rheumatoid factor, and anticardiolipin antibodies.

Authors:  R A Asherson; M Tikly; H Staub; P T Wilmshurst; D J Coltart; M Khamashta; G R Hughes
Journal:  Ann Rheum Dis       Date:  1990-02       Impact factor: 19.103

5.  The heart in systemic lupus erythematosus.

Authors:  R A Barker
Journal:  BMJ       Date:  1989-07-22

Review 6.  Association of antiphospholipid antibodies with valvulopathy in systemic lupus erythematosus: a systematic review.

Authors:  Priscila Mattos; Mittermayer B Santiago
Journal:  Clin Rheumatol       Date:  2011-01-05       Impact factor: 2.980

7.  Systemic lupus erythematosus complicated by tricuspid stenosis and regurgitation: successful treatment by valve transplantation.

Authors:  D E Ames; R A Asherson; J D Coltart; V Vassilikos; J K Jones; G R Hughes
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

8.  Mitral Valve Perforation in Libman-Sacks Endocarditis: A Heart-Wrenching Case of Lupus.

Authors:  Elizabeth S Aby; Zachary Rosol; Mengistu A Simegn
Journal:  J Gen Intern Med       Date:  2016-03-14       Impact factor: 5.128

9.  Cardiac valvular disease in patients with systemic lupus erythematosus. Relationship with anticardiolipin antibodies.

Authors:  Piotr Leszczyński; Ewa Straburzyńska-Migaj; Izabela Korczowska; Jan K Łacki; Stefan Mackiewicz
Journal:  Clin Rheumatol       Date:  2003-10-14       Impact factor: 2.980

Review 10.  Revisiting Libman-Sacks endocarditis: a historical review and update.

Authors:  Jennifer L Lee; Stanley M Naguwa; Gurtej S Cheema; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.